TLM-003 (Therillume)

**TLM-003** is an investigational Therillume neuro-oncology asset listed in the company pipeline for **glioblastoma multiforme**. Publicly available pipeline information identifies it only by the internal code name **TLM-003** and places it in **Phase 1** development for GBM; the archived pipeline notes also indicate it had completed at least a **Phase Ib** study in GBM. No reliable public source identified a molecular target, active ingredient, modality, route, or detailed mechanism of action for the Therillume GBM program, so its pharmacology remains undisclosed based on the available evidence.

Other names

TLM-003-TLM-Glioblastoma MultiformeTLM003-TLM-Glioblastoma MultiformeTLM 003-TLM-Glioblastoma Multiforme